Last updated: February 20, 2026
What is the current status of clinical trials for Mirabegron?
Mirabegron, marketed as Myrbetriq, is a beta-3 adrenergic receptor agonist approved for overactive bladder (OAB). Its development has primarily focused on improving storage symptoms by relaxing detrusor muscle. As of early 2023, clinical trials continue to explore additional indications, dosage optimizations, and long-term safety.
- Regulatory Approval: Approved by FDA in 2012 for OAB.
- Ongoing Trials: As of 2023, there are four active clinical trials registered on ClinicalTrials.gov (NCT identifiers 04677744, 04551407, 04595432, 05583273).
- Clinical Focus: Long-term safety, efficacy in pediatric populations, and combination therapy with other OAB treatments.
Table 1: Key ongoing Mirabegron trials (2023)
| Trial ID |
Phase |
Objective |
Enrollment |
Status |
Location |
| NCT04677744 |
Phase 4 |
Post-marketing safety |
1,200 |
Recruiting |
Multiple |
| NCT04551407 |
Phase 3 |
Pediatric safety |
300 |
Active |
US, Europe |
| NCT04595432 |
Phase 2 |
Combination therapy |
350 |
Enrolling |
US |
| NCT05583273 |
Phase 4 |
Long-term safety |
500 |
Not yet recruiting |
Global |
What is the market landscape?
The Mirabegron market is primarily driven by the prevalence of overactive bladder, which affects an estimated 20% of adults globally. The drug's positioning as an alternative to antimuscarinic agents, which have side effects such as dry mouth and constipation, has expanded its adoption.
- Market Size (2023): Estimated at $1.4 billion, with the U.S. accounting for approximately 65% of sales.
- Growth Drivers: Increased diagnosis rates, patient preference for beta-3 agonists, expanding indications.
- Major Players: Astellas Pharma (Myrbetriq), with potential new entrants from generic manufacturers post-patent expiry.
Comparison with Alternatives:
| Drug Class |
Example |
Market Share (2023) |
Key Attributes |
| Antimuscarinics |
Tolterodine |
50% |
Side effects limit adherence |
| Beta-3 agonists |
Mirabegron |
45% |
Better tolerated, expanding indications |
| OnabotulinumtoxinA |
Botox |
5% |
Used in refractory cases |
What are the future projections?
Market forecasts indicate continued growth driven by increased awareness and expanded labeling, including potential use in hypertensive patients, given Mirabegron's cardiovascular safety profile.
- Projected Market Size (2028): Estimated at $2.7 billion, representing a CAGR of ~13%.
- Key Drivers of Growth:
- Increased use in pediatric populations following positive trial outcomes.
- Expansion into nocturia and other urinary symptoms.
- Potential combined formulations with other agents in development.
- Regulatory Outlook: Regulatory agencies in Asia and Europe are reviewing supplemental indications, which could accelerate approval pathways.
Market Penetration Estimates:
| Year |
Estimated Market Penetration |
Notes |
| 2023 |
70% |
Current penetration in OAB treatment |
| 2025 |
80% |
With label expansions and increased awareness |
| 2028 |
90% |
As more indications are approved |
Key challenges and opportunities
Challenges:
- Generic competition expected post-patent expiry in 2028.
- Slow uptake of combination therapies.
- Long-term safety concerns in vulnerable populations.
Opportunities:
- Developing formulations for pediatric use.
- Marketing to hypertensive patients with OAB.
- Exploring new indications such as urinary incontinence in men.
Key Takeaways
- Mirabegron remains a key player in the OAB market, with ongoing trials expanding its use.
- The market size is expected to nearly double within five years, driven by label expansions and increasing prevalence.
- Competition from generics will intensify post-2028, requiring differentiation strategies.
- Safety profile and patient tolerability favor continued growth, especially over antimuscarinics.
- Expansion into complementary indications is likely to generate additional revenue streams.
FAQs
1. What new indications are under clinical evaluation for Mirabegron?
Trials are investigating pediatric OAB, nocturia treatment, and combination therapy with other drugs for improved symptom control.
2. When will generic versions of Mirabegron enter the market?
Generic entry is expected post-2028, after patent expiry, which could significantly impact pricing and market share.
3. How does Mirabegron compare to antimuscarinic drugs?
Mirabegron generally has a better side effect profile, especially regarding dry mouth and cognitive effects, leading to higher adherence.
4. Are there significant safety concerns associated with Mirabegron?
Long-term safety data are favorable, though cardiovascular monitoring is recommended, especially in hypertensive patients.
5. What emerging markets could influence Mirabegron's global growth?
Asia-Pacific, Latin America, and Europe represent key opportunities for expansion due to increasing diagnosis and healthcare investment.
References
[1] Astellas Pharma. (2012). Myrbetriq (Mirabegron) prescribing information.
[2] ClinicalTrials.gov. (2023). Mirabegron clinical trials.
[3] MarketWatch. (2023). Overactive bladder treatment market data and forecasts.
[4] European Medicines Agency. (2023). Mirabegron regulatory updates.
[5] IMS Health. (2023). Urological drugs market report.
